BETA

12 Amendments of Joëlle MÉLIN related to 2016/2057(INI)

Amendment 4 #
Draft opinion
Recital A
A. whereas protection of health is a fundamental right enshringuaranteed inby the European Convention on Human RightMember States;
2016/10/04
Committee: JURI
Amendment 13 #
Draft opinion
Recital B
B. whereas EUMember States’ public budgets, including those covering health expenditure, are under significant constraints;
2016/10/04
Committee: JURI
Amendment 19 #
Draft opinion
Recital D
D. whereas competition based on smart protectionism can lower costs, reduce expenditure on medicines and improve access to affordable medicines;
2016/10/04
Committee: JURI
Amendment 22 #
Draft opinion
Recital D a (new)
Da. whereas the EU will need to oversee improvements in a range of fields that have an impact on how medicines are produced and distributed;
2016/10/04
Committee: JURI
Amendment 35 #
Draft opinion
Paragraph 1 a (new)
1a. Stresses the importance of observing the principle of subsidiarity, as each Member State must address any shortcomings on the basis of its own particular requirements;
2016/10/04
Committee: JURI
Amendment 36 #
Draft opinion
Paragraph 1 b (new)
1b. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;
2016/10/04
Committee: JURI
Amendment 37 #
Draft opinion
Paragraph 2
2. Considers that exclusive protection periods granted to pharmaceuticals through patents or other mechanisms hinder competition, lead to high prices and negatively impact access to needed medicines;deleted
2016/10/04
Committee: JURI
Amendment 46 #
Draft opinion
Paragraph 2 a (new)
2a. Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome;
2016/10/04
Committee: JURI
Amendment 49 #
Draft opinion
Paragraph 3
3. Recalls that the Pharmaceutical Sector Inquiry Report adopted by the Commission in 2009 showed that manufacturers of medicines have developed abusive strategies in connection with patent claims in order to hinder market entry of generic medicines, which should be avoided;deleted
2016/10/04
Committee: JURI
Amendment 58 #
Draft opinion
Paragraph 4
4. Calls on the Commission to undertake a critical review of the impact of intellectual-property-related incentives on biomedical innovation, to explore alternatives to monopolies for the financing of medical R&D and to evaluate the functioning of the applicable limitations to patent allocations;deleted
2016/10/04
Committee: JURI
Amendment 69 #
Draft opinion
Paragraph 5
5. Calls on the European Patent Office (EPO) and the Member States to grant patents on health products that strictly fulfil the patentability requirements of novelty, inventive step and industrial applicability as enshrined in the European Patent Convention;
2016/10/04
Committee: JURI
Amendment 74 #
Draft opinion
Paragraph 6
6. Calls on the Commission to encourage Member States to fully implement existing patent limitations and flexibilities when confronted with excessive pricing or abuse of monopoly rights;deleted
2016/10/04
Committee: JURI